Below are the most recent publications written about "Etoposide" by people in Profiles.
-
Karmali R, Galvez C, Hamadani M, Gordon L, Winter J, Ma S, Nelson V, Fenske TS, Shah NN, Jagadeesh D, Klein A, Helenowski I, Chen R, Mi X, Petrich A, Evens AM, Pro B. A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen. Blood Adv. 2024 04 09; 8(7):1612-1620.
-
Bryan LJ, Casulo C, Allen PB, Smith SE, Savas H, Dillehay GL, Karmali R, Pro B, Kane KL, Bazzi LA, Chmiel JS, Palmer BA, Mehta J, Gordon LI, Winter JN. Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial. JAMA Oncol. 2023 05 01; 9(5):683-691.
-
Bas Z, Dalvin LA, Tadepalli S, Rao R, Shah A, Leahey AM, Shields CL. Outcomes of Intravenous Chemotherapy (Chemoreduction) for Retinoblastoma Based on Patient Age in 964 Eyes of 554 Patients. Asia Pac J Ophthalmol (Phila). 2021 Jan 19; 10(4):373-380.
-
Pan J, Ghimire S, Alpdogan SO, Chapman A, Carabasi M, DiMeglio M, Gong J, Martinez-Outschoorn U, Rose L, Ramirez M, Wagner JL, Weiss M, Flomenberg N, Pro B, Porcu P, Filicko-OHara J, Gaballa S. Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2021 03; 62(3):590-597.
-
Patel M, Dominguez E, Sacher D, Desai P, Chandar A, Bromberg M, Caricchio R, Criner GJ. Etoposide as Salvage Therapy for Cytokine Storm Due to Coronavirus Disease 2019. Chest. 2021 01; 159(1):e7-e11.
-
Dalvin LA, Bas Z, Tadepalli S, Rao R, Vaidya S, Pacheco R, Shields CL. Risk Factors for Tumor Recurrence Following Primary Intravenous Chemotherapy (Chemoreduction) for Retinoblastoma in 869 Eyes of 551 Patients. J Pediatr Ophthalmol Strabismus. 2020 Jul 01; 57(4):224-234.
-
Shields CL, Bas Z, Tadepalli S, Dalvin LA, Rao R, Schwendeman R, Lally SE, Shields JA, Shah A, Leahey A. Long-term (20-year) real-world outcomes of intravenous chemotherapy (chemoreduction) for retinoblastoma in 964 eyes of 554 patients at a single centre. Br J Ophthalmol. 2020 11; 104(11):1548-1555.
-
Ch?vez-Barrios P, Eagle RC, Krailo M, Piao J, Albert DM, Gao Y, Vemuganti G, Ali MJ, Khetan V, Honavar SG, O'Brien J, Leahey AM, Matthay K, Meadows A, Chintagumpala M. Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Children's Oncology Group Study. J Clin Oncol. 2019 11 01; 37(31):2883-2891.
-
Ozuah NW, Marcus KJ, LaCasce AS, Billett AL. Excellent Outcomes Following Response-based Omission of Radiotherapy in Children and Adolescents With Intermediate or High-risk Hodgkin Lymphoma. J Pediatr Hematol Oncol. 2018 08; 40(6):e338-e342.
-
Kasner MT, Mick R, Jeschke GR, Carabasi M, Filicko-O'Hara J, Flomenberg N, Frey NV, Hexner EO, Luger SM, Loren AW, Mangan JK, Wagner JL, Weiss M, Carroll M, Perl AE. Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. Invest New Drugs. 2018 08; 36(4):657-666.